Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

SAN DIEGO--(BUSINESS WIRE)--#biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced it has appointed Julia Bohannon, Ph.D. and Antonio Hernandez, M.D. to its scientific advisory board. Dr. Hernandez and Dr. Bohannon are inventors of the phosphorylated hexaacyl disaccharide (PHAD) based technology licensed from Vanderbilt University, previously announced on October 6, 2022.

Julia Bohannon, Ph.D. is an Associate Professor in the Department of Anesthesiology and the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center. Dr. Bohannon’s NIH funded research program is aimed at studying clinically relevant immunomodulatory treatments to boost innate immune responses following severe burn injury for the prevention of nosocomial infections, the leading cause of death in surviving burn patients. Utilizing a variety of trauma and infection models, Dr. Bohannon’s studies seek to understand how critical illness causes immune dysfunction and increased susceptibility to infection. The goal of these studies is to develop new approaches to decrease the incidence and severity of infection in critically injured patients.

Dr. Bohannon completed her bachelor’s degree in molecular biology at Eastern Kentucky University. She received her Ph.D. in biomedical sciences from the University of Texas Medical Branch and completed her postdoctoral training at Vanderbilt University Medical Center Department of Anesthesiology. Dr. Bohannon has received numerous research excellence awards for her work, including the Vanderbilt University Medical Center Faculty Clinical and Translational Research Scholar’s Award, the G. Jeanette Thorbecke Award from the Society of Leukocyte Biology, as well as a Maximizing Investigator’s Research Award from the National Institute of General Medicine, which currently funds her studies. She is nationally recognized for her expertise in the field of burn immunology.

Dr. Antonio Hernandez is a Professor of Anesthesiology Critical Care Medicine, Cardiothoracic Anesthesiology, Research at Vanderbilt University Medical Center, Co-Medical Director, CV-ICU. Dr. Hernandez develops new therapies to enhance innate immunity mediated antimicrobial function and protect against inflammation-induced organ injury. His research includes the study of trained immunity to alter the inflammatory response to infection or injury, and has focused on synthetic de novo vaccine adjuvants which are candidates for pharmaceutical development. He employs clinically relevant models of acute sepsis, sepsis-induced immunosuppression, and ischemia reperfusion injury to train the innate immune system to enhance antimicrobial function and reduce organ injury. His clinical interests focus on improving outcomes in critically ill and cardiac surgery patients. His work contributes to ongoing development of new treatment modalities against infections.

Dr. Hernandez received his Bachelor of Science in biology with honors from the University of Texas at El Paso and his Medical Doctorate from the University of Texas Medical Branch at Galveston. After completing an anesthesiology residency at the University of Texas Medical Branch at Galveston, he remained there to complete fellowships in Anesthesiology Critical Care Medicine followed by a fellowship in Cardiothoracic Anesthesiology. He was appointed to the faculty at Vanderbilt University where he also received his Master of Science in Clinical Investigation. In addition to his research, Dr. Hernandez directs the cardiovascular intensive care unit (largest heart transplant program in the world for 3 consecutive years) where he has built perioperative support services for advanced care programs, including total artificial heart, pulmonary endarterectomy, combined heart-lung, and heart-liver transplantation, and various mechanical support services to include extracorporeal membrane oxygenation (ECMO).

“I am thrilled to join Revelation’s SAB and delighted to be able to provide guidance to the team,” said Dr. Bohannon. “The Company has generated compelling data on PHAD, and I am eager to collaborate with, and help guide the scientific team regarding future development plans for PHAD and its potential for treating or preventing infections.”

“Revelation Biosciences is uniquely positioned to continue advancing PHAD to reduce the duration and severity of healthcare associated infection,” said Dr. Hernandez. “I look forward to working with this dedicated and driven team to help shape new approaches for the prevention or treatment of healthcare-associated bacterial infection including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.”

“We are delighted and honored to have such accomplished scientific leaders join our Scientific Advisory Board,” said James Rolke, Chief Executive Officer of Revelation. “Dr. Hernandez and Dr. Bohannon bring a wealth of knowledge and experience in treatment of infection by augmenting the innate immune response, a form of trained immunity. Feedback and collaboration with our SAB will be a vital component of our efforts to develop unique therapies to fulfill currently unmet medical needs.”

For more information on Revelation, please visit www.RevBiosciences.com.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. REVTx‑100 is being developed as a prevention and treatment of bacterial infection. REVTx‑300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, AKI, myocarditis, and NASH. REVTx‑200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑99b is being developed as a treatment for food allergies.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the clinical utility of an increase in intranasal cytokine levels as a biomarker of viral infections; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the potential impact that COVID‑19 may have on Revelation’s suppliers, vendors, regulatory agencies, employees and the global economy as a whole; the ability of Revelation to maintain the listing of its securities on NASDAQ; investor sentiment relating to SPAC related going public transactions; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com

and

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com